Zacks.com on MSN1h
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
ALDX announced that the FDA has accepted its resubmitted new drug application (NDA) for reproxalap, a first-in-class ...
ophthalmologytimes16h
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class ...
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application
Shares of Aldeyra Therapeutics gained after the Food and Drug Administration accepted the company's resubmitted new drug application for its treatment of dry eye disease for review. The stock rose 11% ...
Aldeyra announces FDA acceptance of resubmitted reproxalap application
Aldeyra Therapeutics (NASDAQ:ALDX) announced FDA acceptance of its resubmitted market application for topical ocular ...